The insider sales are too small to carry informational value. Focus on the Crinetics acquisition integration and upcoming earnings for directional cues. Monitor for any larger insider sales post-announcement that could signal skepticism about the deal.
VRTX drugs
VRTX drug pipeline →- ▲ povetacicept 6/10 Filed/PDUFA (BLA under FDA review for accelerated approval in IgAN); Phase 3 (RAINIER in IgAN); Phase 2b/3 (OLYMPUS in p · PDUFA date Nov 30, 2026
- ● inaxaplin 5/10 Phase 2/3
- ▲ ALYFTREK 4/10 Approved
- ● JOURNAVX 4/10 Approved
- ● TRIKAFTA 4/10 Approved
- 6 more · All VRTX drugs, catalysts & trials →
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jul 8 $498.43entry
- T+1 · 4mo ago −0.39%α −1.23% · $496.50
- T+5 · 4mo ago −4.28%α −5.55% · $477.08
- T+20 · 3mo ago −2.73%α −6.00% · $484.83
- T+60 · 7w ago +1.67%α −0.83% · $506.74
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Three Vertex EVPs sold a total of $1.49M in stock over a one-week period ending July 2, 2026, representing less than 0.001% of the company's $134.4B market cap. The sales occurred just before Vertex announced a $10B acquisition of Crinetics Pharmaceuticals on July 7, but the dollar amounts are immaterial and likely reflect routine portfolio management or pre-planned 10b5-1 transactions.
Key Financial Metrics
Key Facts
- Three EVPs (Chief Regulatory & Quality Officer, CMO, Chief Legal Officer) sold shares between June 25 and July 2, 2026.
- Total sales value: $1.49M, or ~0.0011% of Vertex's $134.4B market cap.
- Sales occurred before the July 7 announcement of a $10B acquisition of Crinetics Pharmaceuticals.
- All transactions were open-market sales (code S).
- Non-cash transactions (grants, exercises, tax withholdings) were absent from the cluster.
Financial Impact
Trivial, $1.49M in insider sales is immaterial relative to $134.4B market cap.
Risk Factors
- None material from this cluster; the acquisition integration risk is the primary concern.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-VRTX-1783491146467 |
Track record
21 reports on VRTX
3 of 4 bullish or bearish reports moved the stock their way by T+5. Best: +10.87% at T+60 after the Feb 25, 2026 report. 4 of 4 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry $537.79 Now $531.45 −1.18% settles Nov 24
- Nov 16, 20261d ago 144 Neutral 2/10 Entry $543.10 Now $531.45 −2.15% settles Nov 23
- Nov 16, 20261d ago 144 Neutral 1/10 Entry $544.98 Now $531.45 −2.48% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $542.00 Now $531.45 −1.95% settles Nov 23
- Nov 12, 20265d ago 144 Neutral 2/10 Entry $542.62 Now $531.45 −2.06% settles Nov 19
- Nov 6, 202611d ago 144 Neutral 2/10 Entry $547.09 to $538.60 Now $531.45 −2.86% ▼ −1.55% −4.15% vs SPY
- Nov 2, 202614d ago 8-K Bullish 6/10 Entry $530.76 to $547.89 Now $531.45 +0.13% ▲ +3.23% +3.81% vs SPY
- Oct 22, 202626d ago 3 Neutral 2/10 Entry $523.93 to $558.88 Now $531.45 +1.44% ▲ +6.67% +7.23% vs SPY
- Oct 20, 202628d ago 8-K Neutral 2/10 Entry $524.52 to $521.03 Now $531.45 +1.32% ▼ −0.67% −0.22% vs SPY
- Oct 16, 20264w ago Institutional Cluster Bullish 4/10 Entry $500.36 to $517.49 Now $531.45 +6.21% ▲ +3.42% +3.57% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers